Matthew R. Plooster

All filings by Matthew R. Plooster on record concern Zevra Therapeutics, Inc., in the capacity of board member. In total, 13 filings cover trades dated from 21 April 2015 to 9 March 2023.

Every open-market trade on record is a purchase: 5 purchases worth €67k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants. In 2023 alone, the filings show 1 purchase and no sales.

Half of the purchases are above €4,325 and half below. 5 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. After 5 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +4.9%. These figures describe past trades and do not predict future prices.

The newest entry dates from 13 March 2023: an open-market purchase of €44k, in Zevra Therapeutics, Inc. Half of the filings or more reach the SEC (Form 4) feed on the day of the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.